Multiple Manufacturers

RETACRIT

ASP | WAC | AWP at the HCPCS Unit

Manufacturer:

Multiple Manufacturers

Retacrit HCPCS:

Q5106

HCPCS Code Descriptor:

Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units

Category:

Q Code

Retacrit NDCs:

00069-1307-10, 00069-1306-10, 59353-0004-10, 59353-0220-01, 59353-0003-10, 59353-0002-10, 59353-0120-01, 00069-1311-10, 00069-1318-10, 00069-1305-10, 59353-0120-10, 59353-0220-10, 00069-1308-10, 00069-1309-04, 59353-0010-10

Primary Type:

Oncology Biosimilar

Generic/Specialty Status:

Multi-Source

Package Type:

Vial

Route of Administration:

Subcutaneous

Retacrit CPT Codes:

-96372 - Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular

-96374 - Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); intravenous (IV) push, single or initial substance/drug

-96375 - Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); each additional sequential IV push of a new substance/drug (list separately in addition to code for primary procedure)

Some of the most common CPT administration codes for 'buy and bill' drugs can be found at the following link:

Potential NDC Listing Errors:

We have identified listing errors with the following NDCs:

59353-0010-10, 00069-1309-04, 00069-1308-10, 59353-0220-10, 59353-0120-10, 00069-1305-10, 00069-1318-10, 59353-0002-10, 59353-0003-10, 00069-1306-10, 00069-1307-10, 00069-1311-10, 59353-0004-10

About Retacrit:

RETACRIT is a medication manufactured by multiple manufacturers and aligned to the Q Code: Q5106. RETACRIT is administered via the subcutaneous route of administration.

Retacrit is an injection used to treat patients with anemia caused by a variety of different factors. Retacrit can help treat low red blood cell count in patients with chronic kidney failure, patients receiving treatment for HIV, patients receiving chemotherapy for certain types of cancers, or patients about to undergo surgery. Retacrit works by signalling the bone marrow to produce more red blood cells. It can mimic the substance erythropoietin, which occurs naturally in the body and helps prevent anemia.

ACCESS PRICING AND MORE BY REGISTERING

Q5106 Added Date:

July 1, 2018

Q5106 Effective Date:

January 1, 2020

Q5106 Termination Date:

HCPCS Active

View a Retacrit billing and coding guide at the link below:
Retacrit patient assistance information can be found through Pfizer Rx Pathways at the URL: https://www.pfizerrxpathways.com/
RETACRIT prescribing information can be found at the link below. Please reach out to us if you believe this information to be innacurate or out of date.
Our team has not yet identified a source of side effects information for RETACRIT. Please check back in a few weeks.